Cargando…
Flibanserin: A controversial drug for female hypoactive sexual desire disorder
Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affects quality of life and general well-being. The Food and Drug Administration recently approved flibanserin, for treatment of female hypoactive sexual desire disorder (HSDD), regarded as the most commo...
Autores principales: | Baid, Rashmi, Agarwal, Rakesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198608/ https://www.ncbi.nlm.nih.gov/pubmed/30416308 http://dx.doi.org/10.4103/ipj.ipj_20_16 |
Ejemplares similares
-
Flibanserin for Treating Hypoactive Sexual Desire Disorder
por: Sang, Jae Hong, et al.
Publicado: (2016) -
New developments in the treatment of hypoactive sexual desire disorder – a focus on Flibanserin
por: Jayne, Christopher J, et al.
Publicado: (2017) -
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder
por: Simon, James A., et al.
Publicado: (2022) -
Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin
por: Simon, James A., et al.
Publicado: (2022) -
Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study
por: Naguib, Marianne J., et al.
Publicado: (2021)